The association of the hepatitis B virus infection and diffuse large B-cell lymphoma

Article Figures & Data

Table 1

- Basic clinical data of 602 patients with diffuse large B-cell lymphoma.

Factors	AII	HBsAg(+) group	HBsAg(-) group	P-value
Factors	(n=602)	(n=154)	(n=448)	P-value
Age	59.72 ±14.14	61.57 ± 12.45	59.09 ± 14.61	0.060
Gender				0.955
Male	310(51.5%)	79(51.3%)	231(51.6%)
Female	292(48.5%)	75(48.7%)	217(48.4%)
Stage				<0.001^*
I–II	248(41.2%)	32(20.8%)	216(48.2%)
III–IV	354(58.8%)	122(79.2%)	232(51.8%)
IPI score				<0.001^*
0–2	389(64.6%)	59(38.3%)	330(73.7%)
3–5	213(35.4%)	95(61.7%)	118(26.3%)
B symptoms				<0.001^*
Yes	217(36.1%)	79(51.3%)	138(30.8%)
No	385(64.0%)	75(48.7%)	310(69.2%)
Hans classification				0.635
GCB	256(45.5%)	68(41.2%)	188 (42.0%)
Non-GCB	346(57.5%)	86(58.8%)	260 (58.0%)
Extranodal involvement				0.473
Yes	197(32.7%)	54(35.1%)	143 (31.9%)
NO	405(67.3%)	100(64.9%)	305 (68.1%)
Therapy				0.399
CHOP	74(12.3%)	22 (14.3%)	52 (11.6%)
R-CHOP	336(55.8%)	89 (57.8%)	247 (55.1%)
Other	192(31.9%)	43 (27.9%)	149 (33.3%)
Hepatic impairment				0.001^*
Yes	102(16.9%)	39 (25.3%)	63 (14.1%)
NO	500(83.1%)	115 (74.7%)	385 (85.9%)
Recurrence
Yes	164(27.24%)	46(29.87%)	103(23.0%)	0.035^*
NO	438(72.76%)	108(70.1%)	345(77.0%)

IPI: international prognostic index, GCB: germinal center B cell. Hepatic impairment is defined as ALT/AST or blood bilirubin > the upper limit of normal.
↵* P<0.05 was considered statistically significant.

Table 2

- Univariate analysis of the survival time of 602 patients with diffuse large B-cell lymphoma.

Factors	B	SE	HR	95% CI	P-value
HBsAg(+) group (Yes, No)	0.80	0.15	2.21	1.65–2.98	<0.001^*
Age (≥60 years, <60 years)	0.39	0.15	1.48	1.10–1.99	0.010^*
Gender (Male, Female)	0.02	0.14	1.02	0.77–1.35	0.915
Stage (I–II, III–IV)	0.92	0.17	2.50	1.80–3.47	<0.001^*
IPI score (0–2, 3–5)	1.24	1.15	3.44	2.58–4.58	<0.001^*
B symptoms (Yes, No)	0.52	0.14	1.68	1.26–2.23	<0.001^*
Hans classification (GCB, Non-GCB)	-0.29	0.15	0.75	0.56–1.01	0.055
Extranodal involvement (Yes, No)	0.18	0.16	1.19	0.87–1.63	0.272
Therapy (CHOP, R-CHOP, Other)	-0.06	0.08	0.94	0.81–1.10	0.462

↵* P<0.05 was considered statistically significant. IPI: international prognostic index; GCB: germinal center B cell, HR: hazard ratio, CI: cinfidence interval

Table 3

- Multivariate analysis of the survival time of 602 patients with diffuse large B-cell lymphoma.

Factors	B	SE	HR	95%CI	P-value
HBsAg(+) group (Yes, No)	0.38	0.16	1.46	1.07–1.99	0.017^*
Age (≥60years, <60years)	0.19	0.16	1.20	0.88–1.64	0.242
Stage (I–II, III–IV)	0.34	0.20	1.40	0.95–2.07	0.092
IPI score (0–2, 3–5)	0.88	0.19	2.40	1.67–3.32	<0.001^*
B symptoms (Yes, No)	0.23	0.15	1.26	0.94–1.07	0.122